Florbetapir (18F) is a radioactive diagnostic agent used to detect the presence of amyloid plaques in the brain. It is a radiopharmaceutical that is injected intravenously and then taken up by the brain. Florbetapir (18F) is approved by the US Food and Drug Administration (FDA) for use in positron emission tomography (PET) imaging in adults suspected of having Alzheimer's disease. The scan can help doctors to identify the presence of amyloid plaques, which are a hallmark of Alzheimer's disease, and to differentiate Alzheimer's disease from other forms of dementia.
Florbetapir (18F), also sold under the brand name Amyvid, is a radioactive tracer used in Positron Emission Tomography (PET) scans [1]. It's a diagnostic tool for Alzheimer's disease (AD) that helps doctors see if beta-amyloid plaque buildup is present in the brain [1, 2]. Beta-amyloid plaque is one of the key hallmarks of Alzheimer's disease [3].
Here's a summary of Florbetapir (18F):
- Function: It binds to beta-amyloid plaques in the brain, allowing them to show up during a PET scan [2, 3].
- Use: Diagnose the cause of cognitive impairment in adults by detecting beta-amyloid plaques, which can indicate Alzheimer's disease [1].
- Benefits: Compared to other tracers, Florbetapir (18F) has a longer half-life which allows for better accumulation in the brain, potentially providing a clearer picture during imaging [4].
It's important to note that a positive Florbetapir (18F) scan doesn't necessarily mean you have Alzheimer's disease, and a negative scan doesn't rule it out entirely. Doctors will use this information along with other tests for a complete diagnosis [1].